[Form 4] CME Group Inc. Insider Trading Activity

Rhea-AI Filing Summary

CME Group director Charles P. Carey reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 Class A Common Stock shares at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.

Following the transaction, Carey's beneficial ownership consists of:

• 5,779 shares held indirectly through trust
• 185 shares held indirectly through firm
• 0.375 shares held indirectly through partnership

The Form 4 filing indicates this was a planned acquisition under the director compensation program rather than an open market transaction. No derivative securities were involved in this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carey Charles P

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		879	A	$273.03	5,779	I	by Trust
Common Stock Class A								185	I	By Firm
Common Stock Class A								0.375	I	by Partnership

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Charles P Carey	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CME Group shares did Director Charles P Carey acquire on June 25, 2025?

Director Charles P Carey acquired 879 shares of CME Group Class A Common Stock at a price of $273.03 per share on June 25, 2025. These shares were granted pursuant to the CME Group Director Stock Plan.

What is Charles P Carey's total CME stock ownership after the June 2025 transaction?

Following the transaction, Charles P Carey beneficially owns a total of 5,964.375 shares of CME Group Class A Common Stock, broken down as: 5,779 shares held in trust, 185 shares held by firm, and 0.375 shares held through partnership.

What type of CME stock transaction was reported in the Form 4 filing?

The Form 4 filing reported an acquisition (A) of CME Group Class A Common Stock through a stock grant under the CME Group Director Stock Plan, as amended and restated. The transaction was coded as 'A(1)' in the filing.

Who filed the Form 4 for CME Group Director Charles Carey?

The Form 4 was filed by Jenelle Chalmers on behalf of Charles P Carey on June 26, 2025, one day after the reported transaction date of June 25, 2025.